Team


Ori Choshen

Ori Choshen

CEO & Board Member

Ori has been leading VLX Ventures since its establishment, working with entrepreneurs to build and lead successful biotech and computational biology companies. His contribution is based on his extensive experience in investments, management, strategic planning, and business development.

Prior to joining VLX Ventures in 2013, Ori served as VP Business Development at Xenia VC and as a Director of Business Development at SanDisk, (NSDQ: SNDK) where he managed the Ecosystem Group. Ori joined SanDisk as part of the company’s $1.6 billion acquisition of M-Systems (NSDQ: FLSH) in 2006. Prior to this, Ori held business development and management positions at M-Systems and Hutchison’s global telecom group, managing the Handset Department (Marketing) of Orange Israel, a Hutchison’s subsidiary.

Ori also served as an investment manager in PFC, Orange’s VC subsidiary. Ori holds a B.A. in Philosophy, Cum Laude, and an LLB degree from Tel Aviv University as well as an MBA, Cum Laude, from the Solvay Business School in Brussels.

Elad Duschak

Elad Duschak

Board Member

Strategic Advisor to CBG, Healthcare

Elad has over 20 years of international experience in senior leadership roles in strategy, business development and general management within the healthcare industry, and has deep knowledge of the public and private healthcare sectors, including the pharma, biotech, medical device, and digital health markets.

Elad is currently the Chief Business Development Officer at Operose Health, the UK arm of Centene Corp, a FORTUNE® 50 US government-sponsored health insurer. He is also the founder and Chairman of the Advisory Board of the UK Israel HealthTech Forum. Elad also acts as a senior strategic advisor to CBG, a major UK-based investor in Cleantech and Healthtech with primary focus on the Israeli and EU innovation eco-systems

Elad holds an Executive MBA from the Hebrew University, and a BA in economics and international marketing from ISG in Paris.

Anat Tsour Segal

Anat Tsour Segal

Board Member

Ms. Anat Tsour Segal, seasoned investor, business executive and entrepreneur, creating and advancing the high technology ecosystem in Israel with strong focus on planet, medical and cyber for infrastructure ground breaking technologies addressing major global challenges of the 21st century.

Anat currently serves as Chairwoman of Saturas Ag, an early stage Israeli Ag-tech company engaged in the health of trees, and advises to UK based family office Consensus Business Group. Prior, Anat was founder and CEO of Xenia Venture Capital, an early stage investment firm and technological incubator in the areas of technology and healthcare and CEO of Capital Nature, a technological incubator and investment firm in the areas of renewable energy and sustainability. Anat teaches  sustainability entrepreneurship at the Adelson School of Entrepreneurship at Reichman University.

Erez Meltzer

Erez Meltzer

Board Member

Erez Meltzer is one of the leading business people in Israel with more than 35 years of experience as a Chairman and CEO in various global companies.

He serves as the Executive Chairman and Vice Chairman of leading Israeli companies, mainly in the Agro Tech and BioMed sectors.

He is the former Executive Chairman of Hadassah University Medical Center and the Chairman of Hadasit – Hadassah’s TTO.

He is investing and active in various business areas including biomed and pharma.

 

Maayan Spivak

Maayan Spivak

Board Member

Maayan is the Chief Financial Officer of the Jerusalem Development Authority.

Before that, she worked in the Budget Division of the Ministry of Finance as Local Government Coordinator, where she was responsible for the budgets of the Ministry of the Interior, the Negev Galilee, and the Ministry of Jerusalem and Heritage.

Dr. Lior Carmon

Dr. Lior Carmon

CIO

Lior  is an expert in the fields of  immunology, specifically vaccinology and immune oncology. Holding a PhD and an MBA, he has an in depth understanding of the science and business trends in these markets. Lior is a pioneer in the signal peptide domain, influencing the development of superior vaccines. Over the past 20 years, Lior serves as an investor, entrepreneur and executive at key Israeli biotech companies including VaxilBio, BIoKine, CureTech and Ester Neurosciences.

He has held various positions at Clal biotechnology industries (CBI) fund, culminating his tenure as a VP of Strategic Alliances & Technology Assessment. During his time at CBI, he was a first point of assessment and decision for investment opportunities in all sectors and at all stages of development. He is a founder, CEO, and head of R&D at VaxilBio Ltd. which developed the SPD-based cancer vaccine, ImMucin, and the tuberculosis subunit vaccine, MTBuVax. His work includes 7 publications including a review.

He is also a co-founder and VP of Business Development at two companies in the immune oncology field, Biokine (lead product: BL-8040) and CureTech (lead product: CT011). Lior currently serves as a founder and CEO of Biopharma Investment & Management, a boutique consultancy company. Lior’s MSc Degree is from Tel-Aviv University and his PhD is from the WIS Institute in the field of tumor immunology, specializing in the development of cancer vaccines.

Moran Ben David

Moran Ben David

CBDO

As Chief Business Development Officer at VLX, Moran brings with her a rich interdisciplinary background and skills at the cross-section of pharma drug development, biology and  business and IP law from blockbuster-drugs IP litigation, to evaluation of new technologies, biological and business opportunities as well as management of collaborations worldwide.

Prior to joining VLX, Moran was Head of Business Development at Pharma Two B in Israel and held various business, strategy, and technological leadership positions in global strategic partnership and alliance management at GlaxoSmithKline, Novartis, and Takeda  in Boston. Moran is seasoned in establishing partnerships for early stage innovative projects and clinical development. Before joining the pharmaceutical industry, Moran was a practicing lawyer, specializing in patent litigation for pharmaceutical companies. Moran holds a BS in Biology from Tel Aviv University, a dual degree from IDC in Finance and Law, and an MBA from Boston University.

Eli Sorzon

Eli Sorzon

CFO

Eli  has 13 years experience in accounting and finance, mainly for large publicly traded hi-tech companies. He is a CPA and holds a bachelor’s degree in Business Administration from the College of Management Academic Studies Division.
Prior to joining Xenia in 2007:
• Manager with the accounting firm of Deloitte Brightman Almagor.
• Manager with Goldstein Sabo Tevet, a leading Tel Aviv accounting firm specializing in hi-tech companies traded on NASDAQ and TASE.

Dr. Nadav Klein

Dr. Nadav Klein

CTO

Nadav brings with him a diverse range of experience as a technology expert and researcher in both industry and academia. Nadav is versed in building, managing, and nurturing technology driven teams and startups in the Information Technology, Agtech, and Life Science space.

Nadav’s keen interest and proficiency in Healthcare, Bioinformatics and Artificial Intelligence applications drove him to pursue a rich academic background, spanning a wide range of multifaceted research fields, most notably Computational Biology, Genomics, Bioinformatics, Precision Agriculture, Advanced Data Science, Robotics, Renewable Energy, and Precision Medicine.

His unique ability to combine technological expertise, deep science competence and a strong business acumen is exceptionally rare, even more so in the Venture Capital realm, constituting a significant asset to VLX’s portfolio companies. Nadav holds both a PhD in Bioinformatics from the University of California-Davis, with honors and distinction, and a BSc in Bioinformatics from Tel Aviv University, Magna Cum Laude. He shares his knowledge as a lecturer at the Interdisciplinary Center in Herzliya, Tel Aviv University, and the Technion.

Prof. Ronit Satchi-Fainaro, Ph.D.

Prof. Ronit Satchi-Fainaro, Ph.D.

Advisory Board

Prof. Ronit Satchi-Fainaro is a Professor at Tel Aviv University, where she is Head of the Cancer Research & Nanomedicine Laboratory, Chair of the Department of Physiology & Pharmacology at the Sackler Faculty of Medicine, and Chair of The Kurt and Herman Lion Cathedra in Nanosciences and Nanotechnologies.

She serves on the Board of Directors of Teva Pharmaceutical Industries Ltd., Board of Governors of Tel Aviv University, member of the Scientific Advisory Board of the Blavatnik Center for Drug Discovery, the Israel Cancer Association, the Hospital Universitari Vall d’Hebron – Institut de Recerca, VLX and several Editorial Boards of Scientific Journals.

Ronit has published more than 110 manuscripts, 12 book chapters, edited 2 books, is named inventor on 51 patents, some of which were licensed to pharmaceutical and Biotech companies. She was awarded numerous prestigious grants and prizes among them Fulbright, Rothschild, Wingate, Alon,   and Young Investigator Award of the European Association for Cancer Research.

 

Prof. Gabi Barabash MD, MPH

Prof. Gabi Barabash MD, MPH

Advisory Board

Prof. Gabi Barbash, MD, MPH, currently serves as Director of the Bench to Bedside (BtB) Program of the Weizmann Institute of Science, in Rehovot.

Until September 2015 he served as Director General of the Tel Aviv Sourasky Medical Center and as Professor of Epidemiology and Preventive Medicine at the Sackler School of Medicine, Tel Aviv University.

Gabi was formerly Director General of Israel’s Ministry of Health, Deputy Director of the Sheba Medical Center at Tel Hashomer, and Deputy Surgeon General of the Israel Air Force.

Luba Greenwood,  J.D.

Luba Greenwood, J.D.

Luba Greenwood is a biotech veteran, tech investor and company builder. Luba served as executive at Google Life Sciences (Verily) and Vice President of Global Business Development and Mergers & Acquisitions at Roche, where she also established and led the Innovation Hub for Diagnostics Division. Luba co-founded biotech and digital health companies in the immunotherapy, women’s health and microbiome space, including Incysus and Luca Biologics.

Luba also lectures at Harvard University in the School of Engineering and Applied Sciences, Harvard Medical School, and Harvard Business School, serves on numerous boards, including the Massachusetts Biotechnology Council (MassBio), Brooklyn ImmunoTherapeutics and Entrinsic Health.